Trial Profile
A Phase 2a Trial of Avelumab, an Anti-PDL1 Antibody, in Relapsed and Refractory Peripheral T-cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Anaplastic large cell lymphoma; Extranodal NK-T-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Acronyms AVAIL-T
- 01 Oct 2021 Status changed from active, no longer recruiting to completed.
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 04 Nov 2020 Status changed from recruiting to active, no longer recruiting.